Role of Plasma Lipoproteins in Modifying the Toxic Effects of Water-insoluble Drugs: Studies with Cyclosporine A

Overview

Journal AAPS PharmSci

Specialty Pharmacology

Date 2003 Mar 21

PMID 12646002

Citations 3

Authors

Kishor M Wasan

Manisha Ramaswamy

Mona Kwong

Kathy D Boulanger

Affiliations

Soon will be listed here.

Abstract

Lipoproteins are a heterogeneous population of macromolecular aggregates of lipids and proteins that are responsible for the transport of lipids through the vascular and extravascular fluids from their site of synthesis or absorption to peripheral tissues. Lipoproteins are involved in other biological processes as well, including coagulation and tissue repair, and serve as carriers of a number of hydrophobic compounds within the systemic circulation. It has been well documented that disease states (eg, AIDS, diabetes, cancer) significantly influence circulating lipoprotein content and composition. Therefore, it appears possible that changes in the lipoprotein profile would affect not only the ability of a compound to associate with lipoproteins but also the distribution of the compound within the lipoprotein subclasses. Such an effect could alter the pharmacokinetics and pharmacological action of the drug. This paper reviews the factors that influence the interaction of one model hydrophobic compound, cyclosporine A, with lipoproteins and the implications of altered plasma lipoprotein concentrations on the pharmacological behavior of this compound.

Citing Articles

Lipoproteins as Drug Carriers for Cyclosporine A: Optimization of the Entrapment.

Abdel-Mottaleb M, Boi L, Barra M, Colin J, Berni L, Beduneau A Materials (Basel). 2023; 16(3).

PMID: 36770166 PMC: 9918909. DOI: 10.3390/ma16031156.

Equivalence-by-design: targeting in vivo drug delivery profile.

Chen M, Lee V Pharm Res. 2008; 25(12):2723-30.

PMID: 18956142 DOI: 10.1007/s11095-008-9743-8.

Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases.

Hong Y, Shaw P, Tattam B, Nath C, Earl J, Stephen K Eur J Clin Pharmacol. 2006; 63(2):165-72.

PMID: 17180621 DOI: 10.1007/s00228-006-0240-x.

References

Peteherych K, Wasan K . Effects of lipoproteins on cyclosporine A toxicity and uptake in LLC-PK1 pig kidney cells. J Pharm Sci. 2001; 90(9):1395-406. DOI: 10.1002/jps.1092. View

Wasan K, Cassidy S . Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J Pharm Sci. 1998; 87(4):411-24. DOI: 10.1021/js970407a. View

Ha Y, Barter P . Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp Biochem Physiol B. 1982; 71(2):265-9. DOI: 10.1016/0305-0491(82)90252-8. View

MORTON R, ZILVERSMIT D . Purification and characterization of lipid transfer protein(s) from human lipoprotein-deficient plasma. J Lipid Res. 1982; 23(7):1058-67. View

Tall A, Forester L, Bongiovanni G . Facilitation of phosphatidylcholine transfer into high density lipoproteins by an apolipoprotein in the density 1.20-1.26 g/ml fraction of plasma. J Lipid Res. 1983; 24(3):277-89. View

MORTON R, ZILVERSMIT D . Inter-relationship of lipids transferred by the lipid-transfer protein isolated from human lipoprotein-deficient plasma. J Biol Chem. 1983; 258(19):11751-7. View

Awni W, Sawchuk R . The pharmacokinetics of cyclosporine. II. Blood plasma distribution and binding studies. Drug Metab Dispos. 1985; 13(2):133-8. View

Hesler C, Swenson T, Tall A . Purification and characterization of a human plasma cholesteryl ester transfer protein. J Biol Chem. 1987; 262(5):2275-82. View

Drayna D, Jarnagin A, McLean J, Henzel W, Kohr W, Fielding C . Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature. 1987; 327(6123):632-4. DOI: 10.1038/327632a0. View

10.

de Groen P, Aksamit A, Rakela J, Forbes G, Krom R . Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med. 1987; 317(14):861-6. DOI: 10.1056/NEJM198710013171404. View

11.

Lemaire M, Pardridge W, Chaudhuri G . Influence of blood components on the tissue uptake indices of cyclosporin in rats. J Pharmacol Exp Ther. 1988; 244(2):740-3. View

12.

de Groen P . Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clin Proc. 1988; 63(10):1012-21. DOI: 10.1016/s0025-6196(12)64916-7. View

13.

MORTON R . Interaction of lipid transfer protein with plasma lipoproteins and cell membranes. Experientia. 1990; 46(6):552-60. DOI: 10.1007/BF01939693. View

14.

Schumann R, Leong S, Flaggs G, Gray P, Wright S, Mathison J . Structure and function of lipopolysaccharide binding protein. Science. 1990; 249(4975):1429-31. DOI: 10.1126/science.2402637. View

15.

Bennett W . Renal effects of cyclosporine. J Am Acad Dermatol. 1990; 23(6 Pt 2):1280-5; discussion 1285-7. DOI: 10.1016/0190-9622(90)70355-l. View

16.

Hughes T, Gaber A, MONTGOMERY C . Plasma distribution of cyclosporine within lipoproteins and "in vitro" transfer between very-low-density lipoproteins, low-density lipoproteins, and high-density lipoproteins. Ther Drug Monit. 1991; 13(4):289-95. DOI: 10.1097/00007691-199107000-00002. View

17.

Arnadottir M, Thysell H, Nilsson-Ehle P . Lipoprotein levels and post-heparin lipase activities in kidney transplant recipients: ciclosporin- versus non-ciclosporin-treated patients. Am J Nephrol. 1991; 11(5):391-6. DOI: 10.1159/000168344. View

18.

De Klippel N, Sennesael J, Lamote J, Ebinger G, De Keyser J . Cyclosporin leukoencephalopathy induced by intravenous lipid solution. Lancet. 1992; 339(8801):1114. DOI: 10.1016/0140-6736(92)90707-a. View

19.

Gardier A, Mathe D, Guedeney X, Barre J, Benvenutti C, Navarro N . Effects of plasma lipid levels on blood distribution and pharmacokinetics of cyclosporin A. Ther Drug Monit. 1993; 15(4):274-80. DOI: 10.1097/00007691-199308000-00003. View

20.

Wasan K, Grossie Jr V, Lopez-Berestein G . Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion. Antimicrob Agents Chemother. 1994; 38(9):2224-6. PMC: 284720. DOI: 10.1128/AAC.38.9.2224. View